trial

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCTId NCT00845507
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 54 (actual)
Sponsored by University of Cincinnati
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-12
Primary completion
2015-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Exenatide

Sponsors

University of CincinnatiLead Sponsor
Eli Lilly and CompanyCollaborator

Investigators

1
Melissa DelBello, MDPrincipal Investigator

Sites

1 total
Cincinnati, United States

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE4
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Exenatide
drug
lead_sponsor
University of Cincinnati
company
collaborator
Eli Lilly and Company
company
indication
Weight Gain
indication
Weight Gain
indication
investigator
Melissa DelBello, MD
person